You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer

    SBC: Mekanistic Therapeutics, LLC            Topic: NCI

    PROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A nanoparticle delivery system for CRISPR Cas based therapeutics

    SBC: ATGC Inc.            Topic: NCATS

    Abstract Applications of customizable nucleases such as CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein have enabled efficient and precise gene correction in vitro and hold promises for eventually achieving in vivo gene correction therapy However to apply CRISPR Cas in therapeutic settings several major challenges remain to be addressed ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Fc folate Conjugate for the Treatment of Triple Negative Breast Cancer

    SBC: NeuLink Inc.            Topic: 100

    Abstract According to the American Cancer Society in women in the U S will develop breast cancer at some point in their life and of these women will have triple negative breast cancer TNBC an aggressive subtype of breast cancer that lacks the three receptors ER PR HER that current drug treatment targets tamoxifen Herceptin Because of its aggressive nature and lack of effec ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections

    SBC: TSRL, INC.            Topic: NIAID

    Abstract In the United Statesskin and soft tissue infectionsSSTIsare one of the most common indications for antibiotic treatmentrepresentingof hospital admissions andmillion doctor visits a yearSSTIs range from selflimiting furuncles and cellulitis to life threatening sepsis and tissue necrosisRecent studies suggest more thanof all SSTIs were caused by staphylococcal or streptococcal speciesin par ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor

    SBC: CAYMAN CHEMICAL COMPANY, INCORPORATED            Topic: NIA

    PROJECT SUMMARY Millions of Americans are suffering from the devastation of cognition decline and other neurological dysfunctions due to one of the neurodegenerative diseases of tauopathy Some of the prominent tauopathies include Alzheimer s disease Pick s disease traumatic brain injury and chronic encephalopathy There is no cure for any of the tauopathies and the actual cause or exogenous r ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Novel methods to improve nuclease mediated homologous recombination

    SBC: ATGC Inc.            Topic: NIGMS

    Abstract Gene correction therapy is one of the most important application directions in regenerative medicine Emerging technologies such as CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein Zinc Finger Nuclease ZFN and Transcription Activator Like Effector Nuclease TALEN have enabled efficient and precise gene editing in a wide spectrum of ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Ground state rabbit pluripotent stem cells

    SBC: ATGC Inc.            Topic: OD

    Abstract To evaluate the therapeutic applications of stem cells it is essential to develop translational research using several animal species Rabbit is a useful model for biomedical research It has been used to study a number of human diseases Compared to mice rabbits have a more similar embryology and stem cell biology to those of humans an adult body size comparable to human infants that ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine

    SBC: 490 BIOTECH INC            Topic: 400

    Expressing humanized bacterial luciferase in stem cellsMoving beyond firefly luciferase toexpand the informational capacity of animal models for regenerative medicine Project Summary This Small Business Technology TransferSTTRPhase II project proposes to develop complementary autonomously bioluminescentautobioluminescentin vitro stem cell lines and in vivo small animal model systems that enable th ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government